|
EP3632908A1
|
|
Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
|
|
FR3084254A1
|
|
LANIFIBRANOR DERIVATIVES
|
|
KR20190137803A
|
|
Novel compounds that are inhibitors of BPA / TAA-TEAD interactions and their use in the treatment of malignant mesothelioma
|
|
US2017189375A1
|
|
Method of treatment of a mucopolysaccharidosis
|
|
PH12016502466A1
|
|
Ppar compounds for use in the treatment of fibrotic diseases
|
|
EP3156404A1
|
|
New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
|
|
FR3040057A1
|
|
Azetidine carboxylic compounds
|
|
EP3154543A1
|
|
Ppar compounds for use in the treatment of fibrotic diseases
|
|
WO2015049471A1
|
|
Use of odiparcil in the treatment of a mucopolysaccharidosis
|
|
FR3017867A1
|
|
Novel phenylazetidine carboxylate or carboxamide compounds
|
